Batoclimab: A Phase 3 clinical trial in TED was initiated, with topline results from the TED program expected in the first half of calendar year 2025. A pivotal Phase 2b clinical trial in CIDP was initiated, with initial results from period 1 expected in the first half of calendar year 2024. As previously disclosed, Immunovant expects to have initial results from a Phase 2 clinical trial in Graves’ disease in the second half of calendar year 2023, and expects to have top-line results from the MG clinical trial in the second half of calendar year 2024. Based on strategic portfolio considerations, Immunovant has decided to preserve warm autoimmune hemolytic anemia as a potential indication for IMVT-1402 and not pursue a WAIHA indication for batoclimab.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on IMVT:
- Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
- Immunovant participates in a conference call hosted by Truist
- Wells Fargo upgrades Immunovant to Overweight, raises price target to $27
- Immunovant upgraded to Overweight from Equal Weight at Wells Fargo
- Roivant’s upcoming data readouts could move stock higher, says Cantor Fitzgerald